Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H2 2018, provides an overview of the Women Infertility (Women's Health) pipeline landscape.
Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 13, 17, 17, 1, 22, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 4 molecules, respectively.
Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Table of Contents 2
Introduction 5
Women Infertility - Overview 6
Women Infertility - Therapeutics Development 7
Women Infertility - Therapeutics Assessment 19
Women Infertility - Companies Involved in Therapeutics Development 28
Women Infertility - Drug Profiles 49
Women Infertility - Dormant Projects 176
Women Infertility - Discontinued Products 181
Women Infertility - Product Development Milestones 182
Appendix 192
List of Tables
Number of Products under Development for Women Infertility, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Women Infertility - Pipeline by Addex Therapeutics Ltd, H2 2018
Women Infertility - Pipeline by AlphaMab Co Ltd, H2 2018
Women Infertility - Pipeline by Amega Biotech, H2 2018
Women Infertility - Pipeline by Aprilbio Co Ltd, H2 2018
Women Infertility - Pipeline by Aptorum Group Ltd, H2 2018
Women Infertility - Pipeline by ASKA Pharmaceutical Co Ltd, H2 2018
Women Infertility - Pipeline by Auritec Pharmaceuticals Inc, H2 2018
Women Infertility - Pipeline by Bayer AG, H2 2018
Women Infertility - Pipeline by Bharat Serums And Vaccines Ltd, H2 2018
Women Infertility - Pipeline by Cadila Healthcare Ltd, H2 2018
Women Infertility - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
Women Infertility - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Women Infertility - Pipeline by ElexoPharm GmbH, H2 2018
Women Infertility - Pipeline by EndoCeutics Inc, H2 2018
Women Infertility - Pipeline by Enteris BioPharma Inc, H2 2018
Women Infertility - Pipeline by Evestra Inc, H2 2018
Women Infertility - Pipeline by Evotec AG, H2 2018
Women Infertility - Pipeline by FemmePharma Global Healthcare Inc, H2 2018
Women Infertility - Pipeline by Ferring International Center SA, H2 2018
Women Infertility - Pipeline by Forendo Pharma Ltd, H2 2018
Women Infertility - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018
Women Infertility - Pipeline by Glycotope GmbH, H2 2018
Women Infertility - Pipeline by Immunitor Inc, H2 2018
Women Infertility - Pipeline by Isifer AB, H2 2018
Women Infertility - Pipeline by IVFarma LLC , H2 2018
Women Infertility - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
Women Infertility - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018
Women Infertility - Pipeline by LG Chem Ltd, H2 2018
Women Infertility - Pipeline by Livzon Pharmaceutical Group Inc, H2 2018
Women Infertility - Pipeline by Luye Pharma Group Ltd, H2 2018
Women Infertility - Pipeline by Myovant Sciences Ltd, H2 2018
Women Infertility - Pipeline by Nippon Shinyaku Co Ltd, H2 2018
Women Infertility - Pipeline by NutriBand Inc, H2 2018
Women Infertility - Pipeline by ObsEva SA, H2 2018
Women Infertility - Pipeline by Ogeda SA, H2 2018
Women Infertility - Pipeline by Pangen Biotech Inc., H2 2018
Women Infertility - Pipeline by Philogen SpA, H2 2018
Women Infertility - Pipeline by Predictive Therapeutics LLC, H2 2018
Women Infertility - Pipeline by PregLem SA, H2 2018
Women Infertility - Pipeline by Repros Therapeutics Inc, H2 2018
Women Infertility - Pipeline by Richter Gedeon Nyrt, H2 2018
Women Infertility - Pipeline by SK Chemicals Co Ltd, H2 2018
Women Infertility - Pipeline by Suzhou JiSheng Pharmaceutical Co Ltd, H2 2018
Women Infertility - Pipeline by SYNG Pharmaceuticals Inc, H2 2018
Women Infertility - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Women Infertility - Pipeline by Temple Therapeutics BV, H2 2018
Women Infertility - Pipeline by ValiRx Plc, H2 2018
Women Infertility - Pipeline by Viramal Ltd, H2 2018
Women Infertility - Dormant Projects, H2 2018
Women Infertility - Dormant Projects, H2 2018 (Contd..1), H2 2018
Women Infertility - Dormant Projects, H2 2018 (Contd..2), H2 2018
Women Infertility - Dormant Projects, H2 2018 (Contd..3), H2 2018
Women Infertility - Dormant Projects, H2 2018 (Contd..4), H2 2018
Women Infertility - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Women Infertility, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
